Search through
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine (CAS 666816-98-4) is a critical building block in the high purity fine chemicals segment, specifically serving as a key precursor for the synthesis of Linagliptin within the competitive US API intermediates market. 8-Bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione is increasingly sourced by domestic CDMOs who require Pharma/API purity 99% to ensure compliance with stringent FDA quality systems while navigating global sourcing shifts toward more resilient North American supply chains. 3-Methyl-7-(2-butyn-1-yl)-8-bromoxanthine remains indispensable for custom synthesis services and advanced pharmaceutical research where a General Industry purity 98% is often utilized for initial process optimization, highlighting the need for a reliable bulk chemical supplier capable of providing rigorous analytical validation. We are an established 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione intermediates supplier with >= 99% purity in the united states, ensuring minimal carry-over of impurities in the final API, and a broad range of various pharmaceutical intermediates for API manufacturers and finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione COA/TDS/SDS region-specific regulatory support. reliable lead times, worldwide supply chain capabilities
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine (CAS 666816-98-4) is a critical building block in the high purity fine chemicals segment, specifically serving as a key precursor for the synthesis of Linagliptin within the competitive US API intermediates market. 8-Bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione is increasingly sourced by domestic CDMOs who require Pharma/API purity 99% to ensure compliance with stringent FDA quality systems while navigating global sourcing shifts toward more resilient North American supply chains. 3-Methyl-7-(2-butyn-1-yl)-8-bromoxanthine remains indispensable for custom synthesis services and advanced pharmaceutical research where a General Industry ...
.3d8f8f41.svg)
Pharmaceutical
.3556d45a.svg)
Pharmaceutical Actives & Precursors
Intermediates & Precursors
.7767eb0f.png)
Chemical Properties & Specifications
P261, P305, P338, and P351
Skin Sens. 1 (96.4%)
Eye Irrit. 2A (100%)
A critical organic building block and precursor primarily used in the multi-step synthesis of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin for the management of type 2 diabetes
A functionalized xanthine derivative employed in medicinal chemistry research and industrial manufacturing to develop complex heterocyclic molecules with diverse biological activities
A high-purity standard used in analytical laboratories for quality control, impurity profiling, and structural elucidation during the production of bulk drug substances.
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione is a heterocyclic building block and pharmaceutical intermediate primarily used in the synthesis of Linagliptin, a medication for type 2 diabetes
This compound is widely used in the pharmaceutical industry for drug discovery, research, and the production of active pharmaceutical ingredients
It is slightly soluble in DMSO and methanol and is typically handled as a solid powder or crystal for organic synthesis and laboratory research
Standard specifications include CAS number 666816-98-4, high purity (typically >=98% or >=99%), and documentation such as COA, TDS, impurity reports, and regulatory compliance documents
Scimplify has capabilities for global distribution and custom synthesis through an integrated network of manufacturers and logistics partners with reliable lead time
The product is export ready with a standard MOQ starting from 100 kgs, with lead times for international customers depending on the shipping destination and specific grade.
Category : Pharmaceutical Actives & Precursors
Sub-Category : Intermediates & Precursors
Description : P-Nitrobenzoyl Chloride (CAS 122-04-3) is a critical building block in the API intermediates market,...
